Does Wegovy Cause Stomach Paralysis?
Wegovy (semaglutide) does not cause stomach paralysis, or gastroparesis—a condition where the stomach muscles stop working properly, delaying food emptying. The drug slows gastric emptying as its intended mechanism to promote fullness and weight loss, but clinical data and FDA labeling do not list gastroparesis as a side effect.[1][2] This distinction arises from ongoing patient reports and lawsuits, which often conflate temporary digestive slowdowns with permanent paralysis.
What Gastrointestinal Side Effects Are Confirmed?
Common issues with Wegovy include nausea (44% of users), vomiting (24%), diarrhea (30%), and abdominal pain (20%), mostly mild to moderate and fading after weeks.[3] These stem from GLP-1 receptor agonism, which delays gastric emptying by 20-30% at therapeutic doses without impairing muscle function long-term.[4] Severe cases are rare; less than 1% discontinue due to GI intolerance.
Why Do People Report Stomach Paralysis?
Social media and lawsuits claim gastroparesis from Wegovy or similar drugs like Ozempic, citing symptoms like bloating, reflux, and inability to eat. A 2023 JAMA study found 8 confirmed gastroparesis diagnoses among 45,000 new GLP-1 users, but rates were similar to non-users, suggesting no causal link.[5] Risk factors like prior GI issues or high doses may contribute. Novo Nordisk maintains these are not causally related, with no gastroparesis warnings added to labels.[6]
How Does It Compare to Ozempic or Mounjaro?
Wegovy and Ozempic (both semaglutide) share identical GI profiles; Mounjaro (tirzepatide) reports slightly higher nausea (up to 50%) but similar low gastroparesis signals.[7] All slow motility reversibly—effects resolve upon stopping, unlike true gastroparesis requiring medical intervention.
What Do Regulators and Trials Say?
FDA approved Wegovy in 2021 based on STEP trials (17,000+ participants), showing no gastroparesis cases; post-marketing surveillance tracks GI events without labeling changes.[2][8] European Medicines Agency echoes this. Ongoing monitoring via FAERS database notes unverified reports, but no black-box warning.
When Should You Worry About Symptoms?
Seek care for persistent vomiting, severe pain, or weight loss beyond expected—could signal ulcers, pancreatitis, or unrelated gastroparesis (prevalence ~0.2% in general population).[9] Doctors recommend starting low-dose, eating small meals, and hydrating.
[1] FDA Wegovy Label
[2] Novo Nordisk Prescribing Info
[3] NEJM STEP 1 Trial
[4] Diabetes Care Study on Gastric Emptying
[5] JAMA GLP-1 Gastroparesis Analysis
[6] Novo Nordisk Statement on GI Claims
[7] FDA Mounjaro Label
[8] FDA STEP Trials Review
[9] ACG Gastroparesis Guidelines